Tuesday, January 24, 2006

FDA action on PLAVIX?

Reuters: France's Sanofi-Aventis said on Jan. 24, 2006 it would "vigorously defend" the patent on its blockbuster blood thinner, in response to market rumours that the U.S. Food and Drug Administration had authorised Canada's Apotex to market a copycat version of the drug.

Clopidogrel is the chemical [sic: generic] name of Plavix, Sanofi-Aventis's multibillion dollar blood thinner.

"Sanofi-Aventis recalls that the clopidogrel bisulphate is protected by a patent that is still valid," the company said in a statement, adding: "Sanofi-Aventis will vigorously defends its rights."

No one at the FDA was immediately available for comment.

Plavix is an enantiomer in one of many enantiomer/racemate combos, as discussed earlier on IPBiz.


Post a Comment

<< Home